{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"The proportion of subjects developing donor clonal hematopoiesis","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants assessed for donor clonal hematopoiesis.","reportingStatus":"POSTED","timeFrame":"100 days and 365 days post-transplant","title":"Donor Clonal Hematopoiesis","type":"SECONDARY","unitOfMeasure":"Participants"}